Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution

Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution

US Patent 9346888 · Granted May 24, 2016

Estimated economic value: $10,039,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Humanized anti-ACTH antibodies and use thereof2025
Anti-ACTH antibodies and use thereof2025
Methods of treatment with anti-PACAP antibodies2024
Monoclonal antibodies, compositions and methods for detecting complement factor 2024
Therapeutic antibodies that bind to the serine protease domain of MASP-2 and use2024
Anti-PACAP antibodies and uses thereof2024
Screening method for identifying anti-PACAP antibodies or antibody fragments sui2024
Methods for inhibiting angiogenesis in a subject in need thereof2024
Treatment of headache, migraine and/or photophobia conditions using humanized an2024
Antibodies specifically binding to MASP-3 for the treatment of various diseases 2024
Antibodies specifically binding to MASP-3 for the treatment of various diseases 2024
Antibodies specifically binding to MASP-3 for the treatment of various diseases 2024